相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Carsten Denkert et al.
LANCET ONCOLOGY (2021)
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study
Shu Yazaki et al.
ANTI-CANCER DRUGS (2020)
Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
Zhi-Hua Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia
Gelareh Farshid et al.
PATHOLOGY (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+and HER2 2+/Her2 amplified cases
Silvia Giuliani et al.
VIRCHOWS ARCHIV (2016)
Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade
Tanja Ignatov et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
What Causes Discrepancies in HER2 Testing for Breast Cancer? A Japanese Ring Study in Conjunction With the Global Standard
Shinobu Umemura et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
